Bereich
Urologie
URO · Dept. II
Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters
Schiefer J, Roth J, Krusche B, Prikler L, Leippold T, Schmid H, Lenggenhager C, Ries G, Plasswilm L, Seelentag W, Vontoggenburg F, Engeler D. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2009; 185:689-95.
01.10.2009Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters
01.10.2009Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2009; 185:689-95
Schiefer Johann, Roth Jakob, Krusche Bernd, Prikler Ladislav, Leippold Thomas, Schmid Hans-Peter, Lenggenhager Cornelius, Ries Gerhard, Plasswilm Ludwig, Seelentag Wolf, Vontoggenburg F, Engeler Daniel
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Schmid H, Engeler D. Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. European urology 2009; 56:744-5.
01.10.2009Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
01.10.2009European urology 2009; 56:744-5
Schmid Hans-Peter, Engeler Daniel
Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract]
Putora P, Plasswilm L, Seelentag W, Schiefer J, Schmid H, Engeler D (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract].
01.09.2009Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract]
01.09.2009-
Putora Paul Martin, Plasswilm Ludwig, Seelentag Wolf, Schiefer Johann, Schmid Hans-Peter, Engeler Daniel
EAU Guidelines on Chronic Pelvic Pain
Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, Messelink E, Oberpenning F, de C Williams A. EAU Guidelines on Chronic Pelvic Pain. European urology 2009; 57:35-48.
31.08.2009EAU Guidelines on Chronic Pelvic Pain
31.08.2009European urology 2009; 57:35-48
Fall Magnus, Baranowski Andrew P, Elneil Sohier, Engeler Daniel, Hughes John, Messelink Embert J, Oberpenning Frank, de C Williams Amanda C
Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example
Schiefer J, Roth J, Krusche B, Leippold T, Schmid H, Ries G, Plasswilm L, Seelentag W, Vontoggenburg F, Engeler D. Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example. Physics in medicine and biology 2009; 54:4959-70.
21.08.2009Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example
21.08.2009Physics in medicine and biology 2009; 54:4959-70
Schiefer Johann, Roth J, Krusche B, Leippold T, Schmid Hans-Peter, Ries G, Plasswilm Ludwig, Seelentag Wolf, Vontoggenburg F, Engeler Daniel
The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice
Abt D. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol 2009; 2009 Aug:342-353.
16.08.2009The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice
16.08.2009J Hepatol 2009; 2009 Aug:342-353
Abt Dominik
Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib
Fokt R, Templeton A, Gillessen Sommer S, Öhlschlegel C, Schmid H. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int 2009; 83:122-4.
27.07.2009Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib
27.07.2009Urol Int 2009; 83:122-4
Fokt Ralf-Michael, Templeton Arnoud, Gillessen Sommer Silke, Öhlschlegel Christian, Schmid Hans-Peter
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
Savic S, Casella R, Zellweger T, Forster T, Sulser T, Gasser T, Schönegg R, Spieler P, Dalquen P, Eichenberger T, Mattarelli G, Lehmann K, Schmauss M, Engeler D, Thalmann G, Zlobec I, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International journal of cancer. Journal international du cancer 2009; 124:2899-904.
15.06.2009The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
15.06.2009International journal of cancer. Journal international du cancer 2009; 124:2899-904
Savic Spasenija, Casella Roberto, Zellweger Tobias, Forster Thomas, Sulser Tullio, Gasser Thomas C, Schönegg René, Spieler Peter, Dalquen Peter, Eichenberger Tobias, Mattarelli Gianfranco, Lehmann Kurt, Schmauss Martina, Engeler Daniel, Thalmann George N, Zlobec Inti, Bubendorf Lukas
Das Nierenzellkarzinom - Inzidenz, Diagnostik und Therapie im lokalisierten Stadium
Preusser S. Das Nierenzellkarzinom - Inzidenz, Diagnostik und Therapie im lokalisierten Stadium. Schweizer Zeitschrift für Onkologie 2009; 3/2009:5-7.
01.05.2009Das Nierenzellkarzinom - Inzidenz, Diagnostik und Therapie im lokalisierten Stadium
01.05.2009Schweizer Zeitschrift für Onkologie 2009; 3/2009:5-7
Preusser Stefan
Strahlenbelastung bei der ESWL. Analyse der beeinflussenden Faktoren bei 1850 Behandlungen
Schwab C. Strahlenbelastung bei der ESWL. Analyse der beeinflussenden Faktoren bei 1850 Behandlungen. Urologische Nachrichten 2009
15.04.2009Strahlenbelastung bei der ESWL. Analyse der beeinflussenden Faktoren bei 1850 Behandlungen
15.04.2009Urologische Nachrichten 2009
Schwab Christoph
Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer
Putora P, Plasswilm L, Seelentag W, Schiefer J, Schmid H, Engeler D (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer.
19.03.2009Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer
19.03.200913th Annual SASRO Meeting
Putora Paul Martin, Plasswilm Ludwig, Seelentag Wolf, Schiefer Johann, Schmid Hans-Peter, Engeler Daniel
[EAU guidelines on prostate cancer]
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev V, Schmid H, Zattoni F, European Association of Urology. [EAU guidelines on prostate cancer]. Actas urologicas españolas 2009; 33:113-26.
01.02.2009[EAU guidelines on prostate cancer]
01.02.2009Actas urologicas españolas 2009; 33:113-26
Heidenreich Axel, Aus Gunna, Bolla Michel, Joniau Steven, Matveev Vsevolod B, Schmid Hans-Peter, Zattoni Filliberto, European Association of Urology
Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer
Wyler S, Engeler D, Seelentag W, Ries G, Schmid H. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urologia internationalis 2009; 82:17-23.
01.01.2009Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer
01.01.2009Urologia internationalis 2009; 82:17-23
Wyler Stephen Frederic, Engeler Daniel, Seelentag Wolf, Ries Gerhard, Schmid Hans-Peter
Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität
Schurch B, Al-Khodairy A, Bersch U, Engeler D, Hugonnet C, Kätterer C, Pannek J. Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität. Schweiz Med Forum 2009; 9:284-285.
01.01.2009Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität
01.01.2009Schweiz Med Forum 2009; 9:284-285
Schurch Brigitte, Al-Khodairy Abdul-Wahab, Bersch Ulf, Engeler Daniel, Hugonnet C, Kätterer C, Pannek Juergen
Hodentumore und Peniskarzinome
Vontoggenburg F, Engeler D, Schmid H. Hodentumore und Peniskarzinome - Epidemiologie, diagnostische Schritte, Stadieneinteilung, Therapien. Schweiz Zschr Onkologie 2009; 3:18-22.
01.01.2009Hodentumore und Peniskarzinome
01.01.2009Schweiz Zschr Onkologie 2009; 3:18-22
Vontoggenburg F, Engeler Daniel, Schmid Hans-Peter
Guidelines on chronic pelvic pain
Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, Messelink E, Oberpenning F, de C Williams A. Guidelines on chronic pelvic pain. In: European Association of Urology Guidelines Pocket ed. 2009. 2009.
01.01.2009Guidelines on chronic pelvic pain
01.01.2009
Fall Magnus, Baranowski Andrew P, Elneil Sohier, Engeler Daniel, Hughes John, Messelink Embert J, Oberpenning Frank, de C Williams Amanda C
Ist das Hochrisiko-Prostatakarzinom ein heilbarer Tumor?
Schmid H. Ist das Hochrisiko-Prostatakarzinom ein heilbarer Tumor?. J Urol Urogynäkol 2009; 16 (suppl 1):10-11.
01.01.2009Ist das Hochrisiko-Prostatakarzinom ein heilbarer Tumor?
01.01.2009J Urol Urogynäkol 2009; 16 (suppl 1):10-11
Schmid Hans-Peter
The European Association of Urology (EAU) guidelines methodology: a critical evaluation
Aus G, Plass K, Parsons K, Mitropoulos D, Loch T, Lobel B, Irani J, Hanus T, Chapple C, Schmid H. The European Association of Urology (EAU) guidelines methodology: a critical evaluation. Eur Urol 2009; 56:859-864.
01.01.2009The European Association of Urology (EAU) guidelines methodology: a critical evaluation
01.01.2009Eur Urol 2009; 56:859-864
Aus G, Plass K, Parsons K, Mitropoulos D, Loch T, Lobel B, Irani J, Hanus T, Chapple C, Schmid Hans-Peter
Urologie zwischen Tradition und Innovation - Blasenkarzinom: Was haben wir in den letzten 10 Jahren gelernt?
Danuser H, Baumeister P, Schmid H. Urologie zwischen Tradition und Innovation - Blasenkarzinom: Was haben wir in den letzten 10 Jahren gelernt?. J Urol Urogynäkol 2009; 11:23-26.
01.01.2009Urologie zwischen Tradition und Innovation - Blasenkarzinom: Was haben wir in den letzten 10 Jahren gelernt?
01.01.2009J Urol Urogynäkol 2009; 11:23-26
Danuser H, Baumeister P, Schmid Hans-Peter
Prostataerkranungen. Differentialdiagnose mittels biologischer Marker
Schmid H. Prostataerkranungen. Differentialdiagnose mittels biologischer Marker. The Medical Journal 2009; 16:11-13.
01.01.2009Prostataerkranungen. Differentialdiagnose mittels biologischer Marker
01.01.2009The Medical Journal 2009; 16:11-13
Schmid Hans-Peter